<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200811">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475891</url>
  </required_header>
  <id_info>
    <org_study_id>PRO07050007</org_study_id>
    <nct_id>NCT00475891</nct_id>
  </id_info>
  <brief_title>Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures</brief_title>
  <official_title>Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will help in identifying the best empiric antibiotic option for Linezolid
      resistant Vancomycin-resistant Enterococci (VRE) infections. This research is important
      because it allows the determination of resistance rates to antibiotics that may not be
      frequently tested to by the clinical microbiology laboratory at UPMC-Presbyterian. It also
      will provide antibiotic minimum inhibitory concentrations (MICs) for these pathogens which
      may help in identifying the best empiric antibiotic option for Linezolid-resistant VRE
      infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After 20 linezolid-resistant VRE isolates are identified, genetic relatedness will be
      determined using a method known as Pulse-field gel electrophoresis (PFGE). No patient
      related data will accompany these isolates, nor will any related identifiers. These isolates
      will be tested using standardized susceptibility methods. We will then grow each isolate and
      test via approved laboratory standards (E-test, AB Biodisk, Stockholm, Sweden) to the drug
      linezolid. Those determined to be resistant using this approved methodology will be saved
      until 20 isolates are identified. For resistant isolates found, analytical and molecular
      techniques will be performed to determine the mechanisms of resistance and whether resistant
      isolates are coming from a single source/being transmitted from person to person.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>dead or alive</measure>
    <time_frame>end of study</time_frame>
    <description>health status</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Isolate</condition>
  <condition>Linezolid</condition>
  <eligibility>
    <study_pop>
      <textblock>
        isolates for rectal surveillance
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dr. Harrison's laboratory collected the rectal surveillance isolates for infection
             control purposes. The isolates will be from January 1, 2006 to December 31, 2006.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Potoski, Pharm D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 5, 2014</lastchanged_date>
  <firstreceived_date>May 17, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>isolate</keyword>
  <keyword>infection</keyword>
  <keyword>linezolid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
